Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
This is what's getting me excited:
"The 5.4 tcf of recoverable gas (Best Case) is important as additional support for a proposed agreement with Alaska Gasline Development Corp ("AGDC") to bring gas to southcentral Alaska markets."
216,309 + 119,864 for my SIPP plus I will be topping up my ISA tomorrow.
"the Company has initiated a formal process including the opening of a data room for a potential joint venture, farm-out, or sale of the Copper Deposit ("Transaction")."
Is the non binding offer for a:
1 - JV
2 - Farm Out
3 - Offer for the copper deposit
Can't wait for the JORC.
The open pit and underground potential of Verkhuba have been demonstrated by the modelling of more than 46,000 meters of drilling and numerous geological interpretations by independent resource consultants. There is around 1.4 million tonnes per annum of excess processing capacity from two third-party concentrators within 52km by road of the Copper Deposit. With power and water easily accessible on site, the opportunity for Verkhuba to be put into production quickly and with a low upfront capital cost is compelling and reflected in the interest received to date.
I'm sure they knew 29th March was going to be a bank holiday.
Discussions with Julian Dunkerton and Potential Sponsors regarding a possible offer for the Company remain ongoing alongside the Company’s continued work on its turnaround plan, including its exploration of various material cost saving options, which is expected to be an important element of any such offer. In accordance with Rule 2.6(c) of the Code, the Company has requested, and the Takeover Panel has consented to, an extension of the relevant deadline to 5.00 p.m. on 29 March 2024. By this time Julian Dunkerton must either announce a firm intention to make an offer for Superdry in accordance with Rule 2.7 of the Code or announce that he does not intend to make an offer for Superdry, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This new deadline will only be extended with the consent of the Takeover Panel, in accordance with Rule 2.6(c) of the Code.
In December 2023, ImmuPharma highlighted that Incanthera plc ("Incanthera"), the dermatology and oncology specialist, had concluded a significant commercial skincare deal with Marionnaud (part of the A.S. Watson Group) initially across Europe and with further roll outs across Asia. It confirmed that this deal is expected to generate significant revenues and profitability for Incanthera, in 2024 and beyond.
Since then, Incanthera's share price has performed strongly.
ImmuPharma owns 9.9 million shares in Incanthera, representing a 10.8% holding with a value of £916k (as at close of business on 05 March). In addition, the Company also has 7.3 million warrants in Incanthera, which are exercisable at any time.
This represents a significant financial asset for ImmuPharma.
With progressive positive news flow expected from Incanthera during 2024, it would be anticipated this will have a significant positive impact on the value of the Company's underlying shareholding.
BioAMB is a novel drug that offers a potential improvement on the limiting side effects and poor administration regime of current Amphotericin-B ("AMB") formulations. AMB is one of a last line of agents against serious and life-threatening fungal infections caused by the aspergillus family of fungi.
Although AMB is highly effective, currently marketed AMB formulations may cause serious kidney toxicity and other severe reactions. BioAMB is not a typical reformulation but a Bio-drug entity, which releases AMB as the active agent.
BioAMB, is a groundbreaking amphotericin-B variant that promises both efficiency and safety.
After multiple in vivo studies assessing the Pharmacokinetic/Pharmacodynamic ("PK/PD") and safety profile of BioAMB, the dose-effect relationship has now been assessed in Part 1 of a new dose-range pharmacodynamic study in an aspergillosis rat model. Part 1 has now been completed.
We are pleased to announce that no toxicity related to BioAMB was observed at the active dose.
We will now move forward to Part 2 of the study which will further evaluate the safety of BioAMB at the active dose and confirm the advantage of BioAMB over the other forms of AMB.
It is the intention of ImmuPharma to partner this programme and initial discussions have commenced.
P140 | SLE/Lupus Program
Further to our update announcement on 19 December 2023 and in collaboration with Simbec-Orion, the preparatory steps for the new Phase 3 study are continuing to progress. As we reach key milestones within the study, such as: site initiations; patient recruitment and patient dosing, we will announce updates accordingly.
As a reminder, the progress update in December included:
· Simbec-Orion appointed as the Contract Research Organisation ("CRO"), for the P140 (Lupuzor?) Phase 3 study in SLE;
· Decision to go straight into an international Phase 3 dose-range study, rather than the longer and more expensive Phase 2/3 adaptive study;
· Confirmation that the current Phase 3 study is substantially different from the previous Phase 3 study completed by the Company and incorporates many changes in the protocol, including significantly higher doses; and
· Important further insights into P140's mechanism of action ("MOA") supporting its position as the only non-immunosuppressing molecule in clinical development in the industry, creating a 'first-in-class' treatment for many autoimmune diseases.
P140 | CIDP Program
Progress has also been made in our second late-stage development program, for chronic idiopathic demyelinating polyneuropathy ("CIDP").
We are pleased to announce that Simbec-Orion, has been appointed as the CRO for this program.
In conjunction with Simbec-Orion, an IND application ("INDA") has been prepared for submission to the FDA, incorporating all their previous guidance points.
In addition, an application for Orphan Drug status for CIDP is being submitted in parallel to the INDA.
As background, in 2023, the Company received positive feedback from the FDA at a pre-Investigational New Drug meeting, that confirmed that a Phase 2/3 adaptive clinical trial will be the first pivotal stage study of P140 in patients with CIDP.
The FDA feedback recognised that P140 is suitable to be studied in another disease indication in addition to SLE and this strongly supports the underlying science and mechanism of action of P140 across several auto-immune/inflammatory diseases, again a significant breakthrough for the P140 platform.
Our business model is clear, focused and simple, for the Company to internally advance its development portfolio up to the point whereby we can enter into commercial deals with larger companies within the industry that then assume the responsibility to fund and complete the clinical development of each product through to registration and ultimately, market launch.
The financial business model underlying this approach provides an optimum number of opportunities across a range of indications and commercial deals.
In each of these potential deals we would expect to receive significant up-front payments on signing, with further receipts on achievement of development and/or sales milestones plus royalties on sales.
The therapeutic indications of our products will be entering markets which offer the realistic prospect of multi-billion dollar annual sales, which in turn, will be reflected in the levels of income we expect to be receiving in both the short, medium and long term.
It is this expectation which will drive the fundamental value of the Company and deliver the return on investment to our shareholders.
The re-focus and expansion of our portfolio development including the recent important advances in determining the clinical path through for our late stage P140 platform and elucidating its unique mechanism of action ("MOA") has generated significant interest from a wide range of potential commercial partners.
This commercial interest includes discussions on the non-US rights for P140 ("SLE"); the worldwide rights for P140 ("CIDP") and the worldwide rights for BioAMB.
Whilst there can be no guarantee of completing commercial deals, there are a broad range of discussions currently taking place and the objective is to complete deal(s) across the portfolio in 2024.
ImmuPharma would firstly like to confirm that the financing position of the Company is sufficient for its immediate requirements and it has no current plans to raise equity through the capital markets.
Future cash requirements are fully expected to be met through non-dilutive income derived from the Company's portfolio of assets including, inter alia, new commercial deals on the development portfolio, including the non-US rights for P140 (SLE/Lupus); the worldwide rights for CIDP and for BioAMB. The Company is in active discussions with a broad range of potential commercial partners with the objective of completing deals across the portfolio in 2024.
To put this all into perspective, since the reorganisation of the Company, which was initiated in August 2021, the Board of Directors has greatly simplified the Group corporate structure; reduced staff levels; eliminated unnecessary and expensive overhead costs and most importantly, focused the development portfolio into two areas; Autoimmune and Anti-Infectives.
ImmuPharma now has two late-stage autoimmune development programs through its P140 platform, for both SLE and CIDP. Also in the portfolio are two earlier anti-infective programs, BioAMB and BioCin. Prior to 2021, the portfolio was primarily focused on only P140 for SLE (Lupus). It is from this enhanced and improved development portfolio that our shareholders will see the future value accretion.
From an ongoing financial management perspective, we have seen a massive reduction of more than 75% in the annual overhead cost of the Company, compared to prior to the reorganisation. Hence, the cash needs of the Company are significantly less than historically and, as a consequence, much easier to forecast and manage.
We are expecting to announce our audited Full Year Results in May 2024.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging the release of this announcement on behalf of GENinCode Plc is Matthew Walls, Chief Executive Officer.
GENinCode Plc
("GENinCode" or the "Company")
New NICE Guidance for Ovarian Cancer
Surveillance using the ROCA test is now an option for individuals at high risk of ovarian cancer
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease ("CVD") and risk of ovarian cancer ("OC"), announces that its Risk of Ovarian Cancer Algorithm ("ROCA") test, has received a National Institute for Health and Care Excellence ("NICE") recommendation as the preferred test for OC surveillance in individuals at high risk of ovarian cancer who do not undertake risk reducing surgery. The new NICE guidance[1] is focused on identifying and managing familial and genetic risk of OC.
Each year in the UK, 7,500 women are diagnosed with OC and over half of those will die from the disease. The risk of developing OC is particularly high in individuals who inherit a known pathogenic variant in certain genes such as BRCA1 or BRCA2. It is estimated that up to 170,000 people in the UK may be carriers of a BRCA gene variant. Identifying such individuals through genetic testing will allow the NHS to better mitigate that risk through prevention and/or surveillance.
Preventative surgery to remove both ovaries and fallopian tubes is the standard of care but where this is not possible, or where the patient decides to delay surgery, NICE now recommends that individuals can be offered surveillance using the ROCA test. The NICE committee reviewed various surveillance protocols, as published in the peer reviewed literature, and concluded that the ROCA test was the most accurate with the best detection rate for earlier stages of OC (stage IIIa or lower). Detection of OC at an earlier stage is associated with a better prognosis and treatment.
The ROCA test uses a proprietary algorithm to calculate a woman's individual OC risk based on several clinical factors including age and accumulating Cancer Antigen 125 (CA-125) blood test results. The ability of the ROCA test to interpret changes in an individual's CA-125 level over time through four monthly interval testing was recognised by the NICE committee as an important contributor to its accuracy and ability to detect OC earlier. Additionally, the NICE committee recognised the published evidence that surveillance using the ROCA test would have a cost-saving benefit for the NHS.
Matthew Walls, Chief Executive Officer of GENinCode Plc, said: "Today's publication of NICE guidance is an important milestone for the ROCA test. After many years of academic and corporate investment, the ROCA test h
Are we expecting the sample testing and drilling results to be released together or seperately?
Variation in the preliminary results indicates a likely dipping vein (i.e. the gold mineralisation is not in a vertical structure) but the further analysis being undertaken is expected to assist with the geological interpretation.
The full results of this bulk sample testing are expected to be completed shortly.
Alongside this, the second phase of the Company's drilling programme in Creswick (at Kuboid Hill) is ongoing and further announcements will be made in due course.
Power China is state owned and has a market cap of approx 9.5 billion pounds.
Hasina will have to say yes as the chinese have been lobying for a while.
"A joint proposal with development partner, PowerChina, will shortly be presented to the newly elected Bangladesh Government"
@Searcher - personally I think we will get the green light as Hasina does NOT have any other solution and this time there is no opposition from the locals because everyone knows importing coal to feed the power stations is not a viable long term solution for Bangla.